Author: Ettinger DS, Wood DE, Aisner DL, Akerley W, Bauman J, Chang JY, Chirieac LR, D'Amico TA, DeCamp MM, Dilling TJ, Dobelbower M, Govindan R, Gubens MA, Hennon M, Horn L, Lackner RP, Lanuti M, Leal TA, Leisch LJ, Lilenbaum R, Lin J, Loo BW, Martins R, Otterson GA, Reckhamp K, Riely GJ, Schild SE, Shapiro TA, Stevenson J, Swanson SJ, Tauer K, Yang SC, Gregory K, Hughes M
Year: 2018
AGREE II score: Available
Developer organization: National Comprehensive Cancer Network
Type of cancer: Lung
Patient population: Adult
Location: International
This is a clinical practice guideline for patients with non-small cell lung cancer. The guideline examines the risk factors, classification factors, diagnostic evaluation, pathologic evaluation, staging, predictive and prognostic biomarkers, treatment, and surveillance of lung cancer. Treatment approaches considered include surgery, radiation therapy, and combined modality therapy. The discussion on initial therapy is stratified by disease stage.
AGREE II - Quality of Reporting Assessment:
Scope and purpose: 38.9%
Applicability: 45.8%
Stakeholder involvement: 63.9%
Editorial independence: 79.2%
Rigour: 69.8%
Clarity presentation: 72.2%
